Citations - Morice Philippe

Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10^(-5)) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow... Read more
Published on: 2020-09-16
Source: Morice Philippe
By: Rémi Letestu
Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10^(-5)) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow... Read more
Published on: 2020-09-16
Source: Morice Philippe
By: Rémi Letestu
Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10^(-5)) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow... Read more
Published on: 2020-09-16
Source: Morice Philippe
By: Rémi Letestu
Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10^(-5)) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow... Read more
Published on: 2020-09-16
Source: Morice Philippe
By: Rémi Letestu
Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10^(-5)) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow... Read more
Published on: 2020-09-16
Source: Morice Philippe
By: Rémi Letestu
Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10^(-5)) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow... Read more
Published on: 2020-09-16
Source: Morice Philippe
By: Rémi Letestu
FOXL2 somatic mutation occurs in a high percentage of ovarian adult granulosa cell tumors and DICER1 mutations in a high proportion of Sertoli-Leydig cell tumors. These mutations have only been studied in a limited number of juvenile granulosa cell tumors (JGCTs), and their occurrence and frequency in these neoplasms is... Read more
Published on: 2020-09-10
Source: Morice Philippe
By: Pauline Baillard
CONCLUSION: NACT has a significant impact on the balance of immune-reactive to immune-tolerant subpopulations and a high ratio of CD8+/FOXP3+, CD3+/FOXP3+, and CD68+/CD163+ post NACT was significantly associated with improved outcomes. Whether this could select patients for immunotherapy in the post-operative setting should be investigated.... Read more
Published on: 2020-08-28
Source: Morice Philippe
By: Alexandra Leary
CONCLUSION: This score includes three biomarkers with easily remembered cut-offs that allow us to identify, at the time of diagnosis, those patients with a high risk of relapse (scores of two or three) and those requiring dose escalation.... Read more
Published on: 2020-08-24
Source: Morice Philippe
By: Amandine Maulard

Other Resources

Other Citations

Other Citations

News by Specialization

News by Specialization

Videos

Selection of Videos by Specialization

Latest News

Latest News

Translate »